



FREDERICK F. HERMAN, M.D.
ALLERGY AND CLINICAL IMMUNOLOGY

729 SUNRISE AVENUE, SUITE 200 • ROSEVILLE, CA 95661

(916) 782-4898 • Fax: (916) 782-1183

8730 '00 NOV 15 A6:41

November 14, 2000

Dockets Management Branch, FDA
Dept. of Health and Human Services
Room 1-23
12420 Parklawn Drive
Rockville, Maryland 20857

Dear FDA,

I would like to express my support of Lotronex (alosetron HCl) and its life changing components. I have first-hand experience that Lotronex provides multisymptom relief for female patients with diarrhea-predominant IBS.

When used in the appropriate patients Lotronex has given significant relief of the pain and discomfort associated with IBS. This is the first prescription product approved for IBS in over 15 years, and gives the patients an option of something that does not cause blurred vision or urinary retention. Also, it gives the patients back control of their bowels, and thus control of their life. Imagine having to leave work because you just had an "accident" in your new clothes.

Of course, Lotronex should not be used in patients who are constipated or have a history of constipation or ischemic colitis as spelled out in the package insert. But when used appropriately, Lotronex has given my patients back their dignity.

Thank you,

Fredrick Herman, MD

00P-1499

C 11